dc.contributor.author |
Szász Máté |
|
dc.contributor.author |
Hajdú Mária |
|
dc.contributor.author |
Pesti Natasa |
|
dc.contributor.author |
Domahidy Mónika |
|
dc.contributor.author |
Kristóf Katalin |
|
dc.contributor.author |
Zahár Ákos |
|
dc.contributor.author |
Nagy Károly |
|
dc.contributor.author |
Szabó Dóra |
|
dc.date.accessioned |
2014-11-16T20:25:08Z |
|
dc.date.available |
2014-11-16T20:25:08Z |
|
dc.date.issued |
2013 |
|
dc.identifier |
84890103269 |
|
dc.identifier.citation |
pagination=461-468;
journalVolume=60;
journalIssueNumber=4;
journalTitle=ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/556 |
|
dc.identifier.uri |
doi:10.1556/AMicr.60.2013.4.7 |
|
dc.description.abstract |
Biofilm-forming Staphylococcus epidermidis strains are common cause of the periprosthetic infection. The treatment of the periprosthetic infection is very problematic, so the prevention of these infections by an antibiotic containing prothesis could be an option for prevention.The purpose of the present study was to examine the in vitro effects of drug delivery systems (DDSs), namely Wax 1 and Wax 2 with different vancomycin content: 0.5, 1, 2 and 4 mg. In order to control the antibacterial activity of DDSs killing curve study was performed and in order to determine the antibiotic release and the antibiotic peak concentration from the DDSs biological assay was carried out.The time kill curve studies showed, that both DDSs with all vancomycin concentration decreased significantly the bacterial counts, however, Wax 2 with 4 mg vancomycin significantly decreased the bacterial count than all the other groups.The vancomycin release was the best with the highest peak concentration from DDSs with 4 mg vancomycin contain; it was significantly better than in the other groups, however, no significant difference was observed between Wax 1 and Wax 2 in this respect.These findings suggest that Wax 2 with 4 mg vancomycin content could be a potential agent for clinical use. |
|
dc.relation.ispartof |
urn:issn:1217-8950 |
|
dc.title |
In vitro efficiency of vancomycin containing experimental drug delivery systems |
|
dc.type |
Journal Article |
|
dc.date.updated |
2014-11-16T19:13:24Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
2483179 |
|
dc.identifier.wos |
000327696200007 |
|
dc.identifier.pubmed |
24292089 |
|
dc.contributor.department |
SE/ÁOK/I/Laboratóriumi Medicina Intézet-összevont 2010 -Központi Laboratórium és Kórélettani LabMed tszcsoport |
|
dc.contributor.department |
SE/ÁOK/I/Orvosi Mikrobiológiai Intézet |
|
dc.contributor.department |
SE/ÁOK/K/Ortopédiai Klinika |
|
dc.contributor.department |
SE/GYTK/Gyógyszerészeti Intézet |
|
dc.contributor.institution |
Semmelweis Egyetem |
|